Adherium digital health lists on ASX at 10% premium

Media Release Monsoon Communications Digital health company’s technology improves adherence and patient health in chronic respiratory disease $35m maximum oversubscribed by Aust & international institutions & retail investors 26 August 2015: Digital health company Adherium Limited (ASX:ADR) listed on the Australian Securities Exchange today opening at 55 cents per share, a 10 per cent premium to […]

Adherium $35m ASX IPO to expand sales of digital health technology to improve medication adherence

–          Digital health company’s technology proven to improve adherence and patient health in chronic respiratory disease –          $25.85m in signed commitments, AstraZeneca US$3m cornerstone investment; led by Bell Potter Securities –          First-in-class 10 year Supply and Development Agreement with AstraZeneca –          Technology has been used in 40 projects, across 29 countries, with 32 publications referencing Smartinhaler 5 August 2015 […]

Adherium & AstraZeneca Partner to Improve the Lives of Individuals with Respiratory Disease

23 July 2015. Link here. First-in-class collaboration combining digital health with class leading inhaled medications Long term international supply agreement targeted at AstraZeneca’s patient support programs Adherium’s Smartinhaler proven to substantially improve medication adherence and health outcomes in adults and children New Zealand-based Adherium (NZ) Limited has entered a long term partnership with international pharmaceutical leader […]

Adherium Receives ISO 13485 Certification

June 16, 2015 Link here – Adherium (NZ) Limited (formerly Nexus6) has received ISO 13485 medical device quality management system certification for operations at its New Zealand head office. ISO 13485 is an international quality management standard that covers all aspects of a medical device company’s operations from product development to manufacturing to customer support. It has […]

Nexus6’s Smartinhaler Dramatically Improves Medication Adherence

Link here. July 23rd, 2014. Results published today in the prestigious Journal of Allergy and Clinical Immunology (JACI) announce a ground-breaking increase in adherence with asthma medications for patients provided with a novel device called the Smartinhaler, manufactured by digital health company Nexus6 Ltd. The research was conducted by the highly regarded Woolcock Institute of Medical Research […]

Nexus6 – Sleeper medical technology company stirs.

Friday June 27, 2014. The National Business Review article link here. A local sleeper medical technology company has ambitious plans to move into commercial production, and won’t rule out an initial public offering. Reporter David Williams looks into how the up and coming tech company are developing a smart device to remotely monitor how people with asthma and other […]

Nexus6 Receives FDA Clearance for Latest Smartinhaler

Nexus6 Ltd, has received 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) for its new SmartTouch inhaler monitoring device. June 3rd, 2014. Link here. It is well known that it is difficult for patients to remember to take daily preventative medications over a long term as required for the management of many chronic […]

Nexus6 Steps Up its Global Presence with Three New Appointments

Auckland, New Zealand, September 6th 2013 – Nexus6 Ltd, a digital health company dedicated to improving respiratory care, today announced three appointments to its senior management team following the Company’s successful US$3.6m financing earlier in 2013. Nexus6 is a global leader in the development and manufacturing of intelligent monitoring solutions that improve the management of COPD and […]